The evolution of cell therapy to address unmet medical needs
Drug Target Review
JUNE 19, 2024
MSTX), from 2010, and was also a member of its board of directors from 2011, until Mast’s merger with Savara, Inc. He received a BS in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. SVRA) in April 2017.
Let's personalize your content